tiprankstipranks
Trending News
More News >

Cambium Bio’s Elate Ocular® Phase 3 Trials Approved by FDA

Story Highlights
Cambium Bio’s Elate Ocular® Phase 3 Trials Approved by FDA

Confident Investing Starts Here:

Regeneus Ltd. ( (AU:CMB) ) has shared an update.

Cambium Bio Limited announced that the FDA has approved the protocol for Phase 3 clinical trials of Elate Ocular®, a treatment for moderate to severe dry eye disease. This approval is a significant milestone, following the FDA Fast Track designation, and positions the company to advance Elate Ocular® through its final stages of clinical development. The trials will be conducted across multiple regions, including Australia and the United States, with the goal of meeting FDA requirements for a Biologics License Application. The company anticipates starting patient enrollment in mid-2025 and aims for a top-line data readout by mid-2026.

More about Regeneus Ltd.

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company specializing in innovative biologics for ophthalmology and tissue repair applications. The company leverages proprietary technology based on human platelet lysate to develop novel therapeutics, with a primary focus on ophthalmology. Cambium Bio’s lead product candidate, Elate Ocular®, targets unmet medical needs in dry eye disease treatment, while its stem cell platform, Progenza™, is aimed at therapies for knee osteoarthritis and other tissue repair indications.

YTD Price Performance: -2.50%

Average Trading Volume: 11,618

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$5.52M

Learn more about CMB stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App